このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

electroCore マネジメント

マネジメント基準チェック /24

electroCore'sの CEO はDan Goldbergerで、 Oct2019年に任命され、の在任期間は 4.67年です。の年間総報酬は$ 1.28Mで、 46.9%給与と53.1%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の2.72%を直接所有しており、その価値は$ 1.10M 。経営陣と取締役会の平均在任期間はそれぞれ2.4年と4.2年です。

主要情報

Dan Goldberger

最高経営責任者

US$1.3m

報酬総額

CEO給与比率	46.9%
CEO在任期間	4.7yrs
CEOの所有権	2.7%
経営陣の平均在職期間	2.4yrs
取締役会の平均在任期間	4.2yrs

経営陣の近況

Recent updates

electroCore (NASDAQ:ECOR) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Jan 07

electroCore gains on distribution deal for gammaCore Sapphire in Eastern Europe

Dec 22

electroCore shares jump 9% on positive results in migraine prevention study

Dec 08

CEO報酬分析

electroCore の収益と比較して、Dan Goldberger の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$16m
Dec 31 2023	US$1m	US$601k	-US$19m
Sep 30 2023	n/a	n/a	-US$21m
Jun 30 2023	n/a	n/a	-US$22m
Mar 31 2023	n/a	n/a	-US$22m
Dec 31 2022	US$998k	US$557k	-US$22m
Sep 30 2022	n/a	n/a	-US$21m
Jun 30 2022	n/a	n/a	-US$20m
Mar 31 2022	n/a	n/a	-US$17m
Dec 31 2021	US$1m	US$525k	-US$17m
Sep 30 2021	n/a	n/a	-US$19m
Jun 30 2021	n/a	n/a	-US$19m
Mar 31 2021	n/a	n/a	-US$21m
Dec 31 2020	US$920k	US$500k	-US$24m
Sep 30 2020	n/a	n/a	-US$26m
Jun 30 2020	n/a	n/a	-US$32m
Mar 31 2020	n/a	n/a	-US$39m
Dec 31 2019	US$2m	US$125k	-US$45m

報酬と市場: Danの総報酬 ($USD 1.28M ) は、 US市場 ($USD 678.50K ) の同規模の企業の平均を上回っています。

報酬と収益: Danの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Dan Goldberger (65 yo)

4.7yrs

在職期間

US$1,281,333

報酬

Mr. Daniel S. Goldberger, also known as Dan, has been Chief Executive Officer and Director of electroCore, Inc. since October 1, 2019. Mr. Goldberger served as Executive Chairman at Repro Med Systems, Inc....

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Daniel Goldberger	CEO & Director	4.7yrs	US$1.28m	2.72% $ 1.1m
Thomas Errico	Founder	no data	US$158.13k	3.21% $ 1.3m
Brian Posner	CFO & Corporate Secretary	5.2yrs	US$679.29k	0.10% $ 40.4k
Michael Romaniw	Executive Vice President of Systems & Operations	5.4yrs	データなし	データなし
Donald Melnikoff	Senior Vice President of Engineering	less than a year	データなし	データなし
Mitch Deshon	Vice President of Global Sales & Business Development	less than a year	データなし	データなし
Michael Mansfield	Vice President of Marketing	less than a year	データなし	データなし
Carrie Kochek	Senior Director of Human Resources	3.6yrs	データなし	データなし
Peter Staats	Chief Medical Officer	4.4yrs	US$1.21m	データなし
Joshua Lev	Chief Strategy Officer	2.4yrs	データなし	データなし
Manuel Marques	Senior Vice President of Operations	less than a year	データなし	データなし
Amanda Yanuklis	Chief of Staff	less than a year	データなし	データなし

2.4yrs

平均在職期間

63.5yo

平均年齢

経験豊富な経営陣: ECORの経営陣は経験豊富であると考えられます ( 2.4年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Daniel Goldberger	CEO & Director	4.7yrs	US$1.28m	2.72% $ 1.1m
Thomas Errico	Founder	18.8yrs	US$158.13k	3.21% $ 1.3m
Thomas Patton	Independent Director	4.2yrs	US$165.50k	0.35% $ 140.5k
Frank Cuneo	Independent Chairman of the Board	4.2yrs	US$210.25k	0.088% $ 35.6k
John Gandolfo	Independent Director	4.2yrs	US$155.83k	0.035% $ 14.2k
Patricia Wilber	Independent Director	2.3yrs	US$151.50k	0.12% $ 47.1k
Julie Bruzzone-Goldstein	Independent Director	2.3yrs	US$150.88k	1.08% $ 438.8k
Charles Theofilos	Director	less than a year	データなし	6.5% $ 2.6m

4.2yrs

平均在職期間

64yo

平均年齢

経験豊富なボード: ECORの取締役会は経験豊富であると考えられます ( 4.2年の平均在任期間)。

electroCore マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

electroCore, Inc. Appoints Donald Melnikoff as SVP, Engineering, Regulatory, and Compliance

electroCore, Inc. Appoints Charles S. Theofilos as New Class Iii Member of the Board

electroCore, Inc., Annual General Meeting, Aug 04, 2023

electroCore, Inc., Annual General Meeting, Dec 02, 2022

Co-Founder recently bought US$56k worth of stock

High number of new directors

Recent updates

Forecast to breakeven in 2026

electroCore, Inc. has completed a Derivatives Offering in the amount of $1.446525 million.

electroCore, Inc. has announced a Derivatives Offering in the amount of $1.446525 million.

electroCore, Inc. Appoints Donald Melnikoff as SVP, Engineering, Regulatory, and Compliance

electroCore, Inc. to Report Q1, 2024 Results on May 08, 2024

electroCore, Inc. Announces Results of Truvaga Plus Consumer Study

electroCore, Inc. Announces the Launch of Truvaga Plus® for General Wellness

electroCore, Inc. to Report Q4, 2023 Results on Mar 13, 2024

electroCore, Inc. Appoints Charles S. Theofilos as New Class Iii Member of the Board

Electrocore, Inc. Announces Data Highlighting Non-Invasive Vagus Nerve Stimulation (Nvns) for Treatment of Symptoms of Gastroparesis

electroCore, Inc. to Report Q3, 2023 Results on Nov 08, 2023

electroCore, Inc. Announces the Publication of Two Peer Reviewed Publication of Two Peer Reviewed Publications Supporting the Use of Gammacore ( Non-Invasive Vagus Nerve Stimulation; nVNS) in Patients with Post Traumatic Stress Disorder

electroCore, Inc. Announces Dismissal of All Litigation Related to Its 2018 Initial Public Offering

electroCore, Inc. Reiterates Revenue Guidance for the Year 2023

electroCore, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Electrocore Provides Earnings Guidance for the Second Quarter and Full Fiscal Year 2023

electroCore, Inc., Annual General Meeting, Aug 04, 2023

electroCore, Inc. Reiterates Revenue Guidance for the Year Ending December 31, 2023

electroCore, Inc. Provides Preliminary Earnings Guidance for the Fourth Quarter and Full Year of 2022

electroCore Receives a Determination Letter from Nasdaq Regarding Minimum Bid Price

electroCore, Inc. Launches New Wellness Product Offering for Stress, Anxiety and Sleep, Truvaga

electroCore, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

electroCore, Inc. to Report Q3, 2022 Results on Nov 03, 2022

electroCore, Inc. Provides Revenue Guidance for the Third Quarter of 2022

electroCore sees Q3 revenue below consensus

electroCore is issued 4 new U.S. patents in nVNS therapy

electroCore, Inc., Annual General Meeting, Dec 02, 2022

electroCore, Inc. Announces Publication of a Peer Reviewed Manuscript, Transcutaneous Cervical Vagus Nerve Stimulation Reduces Behavioral and Physiological Manifestations of Withdrawal in Patients with Opioid Use Disorder

electroCore, Inc. Provides Revenue Guidance for the Third Quarter of 2022

electroCore, Inc. to Report Q2, 2022 Results on Aug 04, 2022

electroCore, Inc. Provides Preliminary Unaudited Earnings Guidance for the Second Quarter of 2022

electroCore sees Q2 revenue estimate higher than consensus

Electrocore, Inc. Announces Study of Gammacore Sapphire™ for the Treatment of Post-Covid Syndrome

electroCore Announces Listing Transfer to the Nasdaq Capital Market

Co-Founder recently bought US$56k worth of stock

Electrocore, Inc. Announces Gammacore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers

Electrocore, Inc. Announces Gammacore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

electroCore, Inc. Provides Earnings Guidance for the Second Quarter of 2022

We Think electroCore (NASDAQ:ECOR) Can Afford To Drive Business Growth

High number of new directors

electroCore Announces Publication of Investigator-Initiated Trial Data for SAVIOR-1 in COVID-19 Patients in Frontiers in Neurology

electroCore, Inc. Provides Unaudited Preliminary Revenue Guidance for the First Quarter of 2022

High number of new directors

Consensus EPS estimates fall by 11%

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Price target decreased to US$2.80

electroCore, Inc. to Report Q4, 2021 Results on Mar 10, 2022

electroCore, Inc. Announces Completion of Enrollment in the TRANSIT Study of non-Invasive Vagus Nerve Stimulation (nVNS) in Post-Operative Ileus

electroCore, Inc. Provides Revenue Guidance for the Full Year of 2021

electroCore, Inc. Announces Publication of Premium II Trial of Gammacore (Non-Invasive Vagus Nerve Stimulation; nVNS) for the Prevention of Migraine

electroCore: Pioneering Bioelectronic Medicine

Third quarter 2021 earnings released: US$0.057 loss per share (vs US$0.10 loss in 3Q 2020)

electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Paroxysmal Hemicrania and Hemicrania Continua

Second quarter 2021 earnings released: US$0.06 loss per share (vs US$0.13 loss in 2Q 2020)

Consensus forecasts updated

electroCore, Inc. Announces Revenue Guidance for the Second Quarter of 2021

electroCore, Inc. has completed a Follow-on Equity Offering in the amount of $18 million.

electroCore completes sale of $1.4M of NOL tax benefits

electroCore, Inc. Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation (nVNS) to Improve Clinical Outcomes and Molecular Biomarkers in Parkinson’S Disease Patients

electroCore, Inc. Develops Non-Drug and Non-Invasive Alternative to Pharmaceuticals That Safely and Effectively Stimulates the Vagus Nerve to Communicate with the Brain and Help Optimize the Body’s Own Ability to Control Problems Impacting Its Health

Price target decreased to US$3.50

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.27 loss in 1Q 2020)

electroCore, Inc. Provides Earnings Guidance for the Second Quarter of 2021

electroCore, Inc. Announces Johns Hopkins University School of Medicine Study of Non-Invasive Vagus Nerve Stimulation (nVNS) for Symptomatic Exacerbation of Nausea in Patients with Gastroparesis and Related Disorders

ElectroCore, Inc. Provides Revenue Guidance for the First Quarter of 2020

electroCore, Inc. to Report Q4, 2020 Results on Mar 11, 2021

electroCore, Inc. Announces Exclusive Distribution Agreement with Medistar2 PTY Limited Following Regulatory Approval in Australia

Non-Invasive Vagus Nerve Stimulation (Nvns) Enters New Stage of Covid-19 Research of electrocore, Inc

マネジメント基準チェック /24